The Importance of the Nasal Microbiome in Transmission and Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 619
- 试验地点
- 1
- 主要终点
- Microbiome difference
研究概览
简要总结
Methods: all studies are case control studies on six different groups: normal individuals, non-COVID-19 patients with olfactory dysfunction, COVID-19 positive patients, previous COVID-19 positive patients with prolonged olfactory dysfunction, patients with chronic rhinosinusitis with and without nasal polyps, and patients with CRS initiating intranasal glucocorticoids.. The patients will be included from the ear-, nose, and throat department and the University Clinic for Flavour, Balance, and Sleep Regional Hospital Gødstrup, as well as Flavour Institute, Department of Clinical Medicine, Aarhus University (AU), and the long COVID-19 clinics in Aarhus and Gødstrup.
Microbiome samples will be swabs from the nasal cavity and oral pharynx will be collected and analysed using next-generation sequencing targeting 16S and 18S ribosomal RNA at the Department of Bacteria, Parasite & Fungi at Staten Serum Institute (SSI), Copenhagen, Denmark. Characterization of the microbiome is performed by 16S/18S amplicon-based metagenomics, and data are analyzed by various bio-informatic tools for determination/visualization of alpha/beta diversity as well as principal coordinates analysis (PCoA). Immunological factors will be collected by means of six swabs: in the nasal cavity and used for either flowcytometry or enzyme-linked immunosorbent assay (ELISA).
For comparison, truecut biopsies of the nasal mucosa are collected from a subgroup of patients undergoing surgery in general anaesthesia.
Due to the novelty of the current study, little relevant information from previous literature can be used for power calculation. However, with an alpha of 5% and a power of 80%, the population size for each group should be 42 participants, assuming the occurrence of bacteria differs with 30% between populations. Taking 20% drop out into account, the investigators aim to include 60 patients in each group.
Perspectives:
The perspectives of this study is to begin bridging the gap between gut and upper airway microbiome and immunology research. Looking at the explosion of interest in the gut, and in personalized medicine in general, the investigators likewise foresee a huge potential for both general and individual prevention and treatments starting with a deeper understanding of the nasal microbiome and immunology. Examples beyond the scope of this study could be microbiome transplants for chronic sufferers of diseases such as chronic rhinosinusitis, allergies or asthma, or in selecting which patients could reap the benefits of the expensive biological treatments emerging on the market.
详细描述
Hypotheses
The following null hypotheses are suggested:
- The nasal microbiome in patients with olfactory dysfunction does not differ from healthy individuals with normal olfaction
- Seasonal fluctuations in the nasal microbiome do not occur
- The immunologic landscape of the nasal mucosa does not correlate with specific microbi-omes
- Neither intranasal glucocorticoids nor dupilumab and mepolizumab affect the nasal mi-crobiome and local immune factors in patients with CRSwNP Materials and methods Design: Case-control study and longitudinal cohort study.
Populations:
- 60 healthy controls: Normal sense of smell and absence of sino-nasal disease, upper air-way allergies, and no intranasal medication
- 60 non-COVID-19 patients with olfactory dysfunction
- 15 COVID-19 positive patients in the acute phase
- 60 long COVID-19 patients with olfactory dysfunction persisting for more than 12 weeks
- 60 patients with CRS initiating intranasal glucocorticoids
- 15 patients with CRS initiating biological treatment
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •Does not wish to participate in study
结局指标
主要结局
Microbiome difference
时间窗: 6 months
Difference in microbiome between the defined groups
次要结局
- Effect of nasal glucocorticoids on nasal microbiome(6 months)
- Correlation between TDI score and nasal microbiome(6 months)
